MedPAC’s Message To Congress: Drug Pricing Still Needs Attention
Executive Summary
The US Medicare Payment Advisory Commission is continuing its work on proposals to overhaul federal payment for physician administered drugs. That is an ominous message for the biopharma industry as it reels from passage of dramatic pricing legislation earlier this year.
You may also be interested in...
HHS Drug Pricing Proposals: Some Things Are Off The Table
The US Centers for Medicare and Medicaid Services is proposing an interesting package of innovative pricing policy changes, but some of the topics not included might be as important as the ideas that are.
Accelerated Approval Price Caps: Policy Has High Profile Support – But Can It Be Done?
US Medicare Payment Advisory Commission likely to recommend that drugs granted Accelerated Approval be subject to some form of price cap when confirmatory clinical data is lacking. The idea has a lot of supporters, but even they seem a bit unclear about how it could actually work.
The Future Of Rebates: MedPAC Will Be Watching For Pricing Law Impacts
The US Medicare Payment Advisory Commission is finally able to analyze the impact of rebates on actual prescription drug spending – but immediate recommendations may not be viable given the changes coming from implementation of the Inflation Reduction Act.